Swab‐based anal cancer screening in men living with HIV : Projected outcomes for different screening algorithms
International Journal of Cancer · 2025
DOI: 10.1002/ijc.70046 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Kirsten Rozemeijer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Anus Neoplasms, HIV Infections, Early Detection of Cancer, Papillomavirus Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Screening for and treatment of anal cancer precursor lesions, high‐grade squamous intraepithelial lesions (HSIL), can prevent anal cancer. Recent guidelines set by the International Anal Neoplasia Society recommend digital anal rectal examination (DARE) and anal swab‐based screening of high‐risk individuals by means of high‐risk (hr)HPV testing or cytology. We used our biobank containing data of more than 600 high‐resolution anoscopy (HRA) screened participants (94% men with HIV) to compare the possible screening algorithms. We selected the 298 screening participants in whom anal swabs were successfully tested for hrHPV and cytology, parallel to HRA screening (DARE followed by complete visual inspection by HRA). We compared outcomes of several strategies (single‐test, co‐testing, two‐step testing) with one or two positive tests required for HRA referral, resulting in 20 possible screening algorithms. We also assessed the sensitivity of DARE to detect anal cancer. We found that the percentage of missed HSIL was lowest with hrHPV testing, either alone (14.2%) or combined with cytology (≥ASCUS threshold: 4.4%; HSIL threshold: 8.8%) (co‐testing or two‐step testing, with ≥1 positive test required for HRA referral). Using these screening algorithms, 61.0 %, 79.0 %, and 63.7% of the participants were referred for HRA. While in some scenarios a small percentage of cancers was missed, all were detected by DARE. Whatever strategy is chosen, screening outcomes will have to be monitored closely to evaluate the program and make adaptations when necessary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
- Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
- Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
- Center for Sexual Health, Department of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, The Netherlands.
- Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.
ORCID-Profile: Kirsten Rozemeijer, Fernando Dias Gonçalves Lima, Renske D M Steenbergen
Zitieren
APA
Rozemeijer, K., Dias Gonçalves Lima, F., Kuyvenhoven, E. J., de Vries, H. J. C., Steenbergen, R. D. M., Prins, J. M., & Siegenbeek van Heukelom, M. L. (2025). Swab‐based anal cancer screening in men living with HIV : Projected outcomes for different screening algorithms. International Journal of Cancer. https://doi.org/10.1002/ijc.70046
Vancouver
Rozemeijer K, Dias Gonçalves Lima F, Kuyvenhoven EJ, de Vries HJC, Steenbergen RDM, Prins JM, et al. Swab‐based anal cancer screening in men living with HIV : Projected outcomes for different screening algorithms. International Journal of Cancer. 2025. doi:10.1002/ijc.70046
BibTeX
@article{Rozemeijer2025,
author = {Rozemeijer, Kirsten and Dias Gonçalves Lima, Fernando and Kuyvenhoven, Esther J and de Vries, Henry J C and Steenbergen, Renske D M and Prins, Jan M and Siegenbeek van Heukelom, Matthijs L},
title = {Swab‐based anal cancer screening in men living with HIV : Projected outcomes for different screening algorithms},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.70046}
}
EUVIMED